

**SARC Biannual Meeting**

November 5, 2009

8:00 am - 12:00 pm

**AGENDA**

<b>8:00 – 8:15</b>	<b>Welcome/SARC Update</b>	Laurence Baker <i>Chair, SARC Board of Directors</i>
<b>8:15 – 9:20</b>	<b>Chawla/Rosenfeld Developmental Therapeutics Symposium</b> PET Evaluation of Sarcoma Treatment Response: “PERCIST” Criteria Assessing Response in Sarcomas: Methods Are Clear; Results Are Murky	Richard Wahl Scott Schuetze
<b>9:20-9:35</b>	<b>Brief Update: Selected Ongoing and Recently Completed SARC Trials</b> <ul style="list-style-type: none"><li>• SARC 003 Phase 2 Gemcitabine/Docetaxel in Bone Sarcoma</li><li>• SARC 004 Phase 2 Neoadjuvant Imatinib in DFSP</li><li>• SARC 005 Phase 2 Adjuvant Therapy High Risk Uterine Leiomyosarcoma</li><li>• SARC 007 Phase 2 Perifosine in chemoinensitive sarcoma</li><li>• SARC 009 Phase 2 Dasatinib in metastatic sarcoma</li></ul>	Laurence Baker
<b>9:35-9:50</b>	<b>Break</b>	
<b>9:50-10:10</b>	<b>New Directions in Therapy for MPNST</b> <ul style="list-style-type: none"><li>• SARC 006 Phase 2 Sporadic vs. NF-associated MPNST</li><li>• SARC 016 Phase 2 RAD001 with and without bevacizumab in metastatic MPNST</li></ul>	Brigitte Widemann
<b>10:10-10:30</b>	<b>Rationale and Study of IGF-1R in Ewing Sarcoma</b> <ul style="list-style-type: none"><li>• SARC011 Phase 2 IGF-1R in Ewing’s in selected sarcoma subtypes</li><li>• SARC013 Phase 3 Chemotherapy and R1507 or placebo in metastatic Ewing’s</li></ul>	Lee Helman Alberto Pappo Paul Meyers
<b>10:30-10:50</b>	<b>Advancing Care of GIST Patients</b> <ul style="list-style-type: none"><li>• SARC 015 Phase 2 R1507 in wild-type GIST</li><li>• SARC 009 Phase 2 Dasatinib in metastatic GIST</li><li>• SARC 019 Phase 3 Imatinib PK testing in metastatic GIST</li></ul>	George Demetri Katie Janeway Jonathan Trent Suzanne George
<b>10:50-11:10</b>	<b>Src Kinase Inhibition of Osteosarcoma</b> <ul style="list-style-type: none"><li>• SARC 012 Phase 2 Sarcatinib in recurrent osteosarcoma/SARC009 Dasatinib in the osteosarcoma cohort</li></ul>	Su Young Kim
<b>11:10-11:30</b>	<b>Collaboration with EORTC</b> <ul style="list-style-type: none"><li>• EORTC 62091/SARC020 Phase 2b EORTC study of ET743 in metastatic STS</li></ul>	Bihn Bui
<b>11:30-12:00</b>	<b>Closed Session: SARC Business Update</b> (SARC Participants Only)	